We are pioneers in harnessing bacteria as a novel and revolutionary class of medicines: Live Biotherapeutics
We understand that bacteria in the human intestine - known as the gut microbiome - have an important function in many diseases.
Importantly, we understand how they function and how they could be used as a revolutionary new class of medicines known as Live Biotherapeutics.
Our deep understanding of bacterial functionality enables us to develop Live Biotherapeutics for a large number of diseases including cancer, gastrointestinal disease, respiratory disease and central nervous system disease.
What makes 4D pharma different?
We understand that the bacteria of the gut microbiome have an important function in health and disease, but importantly – we understand how they function, and how they could be used as potential new therapies.
Watch our video below to find out more about our approach.
Understanding how they function means that our Live Biotherapeutics are potentially providing new and effective treatments for IBS and Crohn’s Disease and game-changing treatments for cancer, asthma and autoimmune conditions such as rheumatoid arthritis and multiple sclerosis.
4D and the Live Biotherapeutics we develop have the potential to transform he way in which many challenging diseases are treated.
What sets us apart?
- We are targeting a new, safer approach to drug development
- We are a fully integrated microbiome company with the capability to progress from research to production to clinic
- We understand mechanism: how our products exert their therapeutic effects and act as a drug
- We have developed and wholly own the largest intellectual property estate in the field
We have laid foundations that have positioned 4D to transform the sector; with four clinical programmes set to deliver data and a number of development programmes heading towards the clinic, 4D will play the lead role in defining the microbiome space.